Biogen reports 52-week phase 2 data for lupus skin drug litifilimab

October 2, 2026 11:20 AM

Biogen Inc. (Nasdaq: BIIB) announced 52-week results from the Phase 2 portion of its ongoing AMETHYST Phase 2/3 study evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found